Physician profile
Michael E Jones
NPI 1841226842
$5,843.21
in general payments reported to CMS, 2019-2025
26 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $403 · 2021: $766 · 2022: $404 · 2023: $1,066 · 2024: $1,032 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,797 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.81 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.43 | 2023-2025 | |
| Emd Serono, INC. | $723.69 | 2019-2025 | Mavenclad, Mavenclad |
| Acadia Pharmaceuticals INC | $715.20 | 2020-2023 | Nuplazid |
| Biogen, INC. | $578.44 | 2020-2025 | Vumerity, Tysabri, Tysabri |
| Neurocrine Biosciences, INC. | $495.28 | 2023-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $483.67 | 2020-2025 | |
| Lilly USA, LLC | $396.24 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Teva Pharmaceuticals USA, INC. | $299.20 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Amneal Pharmaceuticals LLC | $296.13 | 2020-2025 | Crexont |
| Ucb, INC. | $228.66 | 2019-2025 | Briviact, Nayzilam |
| Eisai INC. | $175.34 | 2024-2025 | |
| Adamas Pharmaceuticals, INC. | $147.44 | 2019-2021 | |
| Pfizer INC. | $62.84 | 2024-2025 | |
| Genentech USA, INC. | $53.67 | 2019-2025 | Ocrevus Zunovo |
| Si-Bone, INC. | $51.72 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.84 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $36.59 | 2021 | |
| Supernus Pharmaceuticals, INC. | $33.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.20 | 2020 | |
| Aucta Pharmaceuticals, INC. | $20.06 | 2025 | Motpoly Xr |
| Amylyx Pharmaceuticals, INC. | $17.25 | 2023 | Relyvrio |
| Allergan, INC. | $17.09 | 2021 | |
| Celgene Corporation | $16.96 | 2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $14.52 | 2025 | |
| Jazz Pharmaceuticals INC. | $14.18 | 2025 | |
| Kyowa Kirin, INC. | $13.72 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.